IN8bio, Inc. (INAB)

NASDAQ: INAB · Real-Time Price · USD

1.210

-0.170 (-12.32%)

At close: Dec 19, 2025, 4:00 PM EST

1.200

-0.010 (-0.83%)

After-hours: Dec 19, 2025, 7:59 PM EST

IN8bio Employees

IN8bio had 18 employees as of December 31, 2024. The number of employees decreased by 13 or -41.94% compared to the previous year.

Employees

18

Change (1Y)

-13

Growth (1Y)

-41.94%

Revenue / Employee

n/a

Profits / Employee

-$1,147,667

Market Cap

5.61M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	18	-13	-41.94%
Dec 31, 2023	31	5	19.23%
Dec 31, 2022	26	7	36.84%
Dec 31, 2021	19	5	35.71%
Dec 31, 2020	14	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	92,900
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000

Employee Rankings

INAB News

1 day ago - IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell Engager - GlobeNewsWire
6 weeks ago - IN8bio Reports Third Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
7 weeks ago - IN8bio Expands INB-100 Phase 1 Clinical Trial with Addition of The Ohio State University as New Site - GlobeNewsWire
7 weeks ago - IN8bio Presents T cell Engager Data Demonstrating Deep B Cell Depletion for Autoimmune Indications - GlobeNewsWire
4 months ago - IN8bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
6 months ago - IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial - GlobeNewsWire
7 months ago - IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free Survival - GlobeNewsWire
7 months ago - IN8bio Presents Preclinical Data Highlighting Potential of INB-619 T Cell Engager (TCE) for Autoimmune Disease at ASGCT 2025 - GlobeNewsWire